Compare Quest Diagnostics Inc (DGX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Johnson Controls International PLC — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Johnson Controls International PLC trades at $145.7 (market cap $88.61B). The key difference: Johnson Controls International PLC is far larger — about 3.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | JCI | |
|---|---|---|
Market Cap | $22.80B | $88.61B |
Sector | Health | Industrials |
52-Week High | $216.02 | $148.21 |
52-Week Low | $166.42 | $103.24 |
Enterprise Value | $28.82B | $97.44B |
Dividend Yield | 1.67% | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Johnson Controls International (JCI) trades at $143.93, up 0.78% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.33. Revenue for 2025 reached $23.60 billion, with net income surging to $3.29 billion, reflecting a robust profit margin of 13.94%. Recent corporate actions include a $0.40 dividend payment scheduled for July 2026, and positive news flow highlights growth in smart home and building efficiency markets.
JCI presents a favorable investment case driven by earnings momentum, solid profitability, and a unanimous analyst buy consensus with a $158.29 price target. Key risks include elevated valuation multiples (P/E of 43.67) and rising debt-to-asset ratios, which could pressure returns if growth slows. The stock's proximity to its 52-week high suggests limited near-term upside, but operational execution and sector tailwinds support a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
